Trial Profile
CTLA-4 blockade with MDX-010 [ipilimumab] to induce graft-versus-malignancy effects following allogeneic hematopoietic stem cell transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 24 Jan 2006
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Leukaemia; Lymphoma; Solid tumours
- Focus Therapeutic Use
- 24 Jan 2006 New trial record.